In order to resolve a civil investigation into the marketing of Risperdal for unapproved uses, Johnson & Johnson will pay more than $1 billion to the U.S. Government and states. Negotiations over possible criminal pleas by J & J are ongoing.
Read more Discuss →
Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.
Mad in America has made some changes to the commenting process. You no longer need to login or create an account on our site to comment. The only information needed is your name, email and comment text. Comments made with an account prior to this change will remain visible on the site.